Last reviewed · How we verify
NCT03622931: TRACEII
Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines
Phase 2 trial testing Standard chemotherapy in Ovarian Cancer in 21 participants. Terminated before completion.
1 January 2019
Quick facts
| Lead sponsor | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 21 |
| Start date | 1 February 2014 |
| Primary completion | 1 January 2019 |
| Estimated completion | 17 January 2019 |
| Sites | 13 locations across Germany |
Drugs / interventions tested
- Standard chemotherapy — full drug profile →
- Romiplostim (ROMIPLOSTIM) — full drug profile →
- Placebos — full drug profile →
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
Sponsor
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH — full company profile →
Who can join
18 and older, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety of secondary chemotherapy induced thrombocytopenia (reduction in platelets which leads to bleeding) prophylaxis with romiplostim in ovarian cancer subjects receiving myelosuppressive (blood cell damaging) chemotherapy.It is anticipated that Romiplostim, when administered at an effective dose and schedule, will be a well-tolerated treatment for subjects experiencing chemotherapy-induced thrombocytopenia.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trials.
Lai Y, Pan Q, Wang S, Luo Q, et al · · 2025 · PMID 41403445 · DOI 10.3389/fphar.2025.1683857
Verify or expand the search:
- PubMed search for NCT03622931
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Standard chemotherapy
Trials testing the same drug.
- NCT07260058 — Immune Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · not yet recruiting
- NCT06856187 — Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal C · Phase 2 · recruiting
- NCT04065139 — Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study · Phase 2 · completed
- NCT03398291 — Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy · Phase 3 · unknown
- NCT00643565 — A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma. · Phase 2 · completed
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH trials
Trials by the same sponsor.
- NCT02335268 — Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thr · Phase 2 · completed
- NCT01509560 — PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-ho · Phase 2 · completed
- NCT01320111 — Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment · Phase 2 · completed
- NCT01081431 — Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPS · Phase 2 · completed
- NCT01090089 — Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03622931 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
- Last refreshed: 8 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03622931.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing